OBJECTIVES: To explore the clinical effect of Insulin glargine U300 combined with oral medicine in the treatment of type 2 diabetes.

METHODS: 79 patients with type 2 diabetes admitted from October 2021 to January 2023 were randomly divided into non glargine group (39 cases) and U300 group (40 cases). Patients in the non glargine group and U300 group were treated with oral hypoglycemic drugs only and oral hypoglycemic drugs + Insulin glargine U300 for three months, respectively. The blood glucose, glucose fluctuation and the insulin function related indicators in the two groups were compared after treatment, and the adverse reactions such as hypoglycemia were also evaluated. Statistical analysis was performed using SPSS 22.0.

RESULTS: There were no significant differences in baseline characteristics between two groups. After treatment, the FBG in the U300 group (4.65±1.33 mmol/L) were significantly lower than those in the non glargine group (5.21±1.40 mmol/L) (P<0.05). The HbA1c in the U300 group (6.06±0.89%) were significantly lower than those in the non glargine group (7.15±0.79%) (P<0.05). The maximum blood glucose fluctuation in the U300 group (4.10±1.05 mmol/L) were significantly lower than those in the non glargine group (5.28±1.13 mmol/L) (P<0.05). The fasting C-peptide (2.41±1.02 ug/L) were significantly higher than those in the non glargine group (2.05±0.36 ug/L) (P<0.05). No significant difference were observed in hypoglycemic reaction rates between the U300 group (2.50%, 1/40) and the non glargine group (2.56%, 1/39) (P>0.05).

CONCLUSIONS: The addition of Insulin glargine U300 treatment can better improve the blood glucose management effect of type 2 diabetes, and improve the insulin function. The application effect is safe and reliable.